By Topic
Arafura Rare Earths (ASX: ARU) — Building Australia’s Rare Earth Future
Arafura Rare Earths (ARU) is progressing its flagship Nolans NdPr Project in the Northern Territory — a fully integrated mine-to-separation operation targeting strategic electrification supply chains. With formal government backing, advanced engineering progress, and off-take partnerships in motion, ARU is positioning itself as a critical rare-earth supplier to global EV and wind OEMs.
Arafura Rare Earths's (ASX: ARU) share price is trading at a strong support level, is it a buying opportunity?
Arafura Rare Earths (ASX: ARU) is trading near a key support zone after recent volatility, where buyers have previously stepped in. Strength in rare earth prices adds sector momentum. While this mix may signal opportunity, confirmation depends on support holding and the company delivering meaningful project progress.
European Lithium (ASX: EUR) has reached our target price already! Here's what happened.
European Lithium (ASX: EUR) hit its target price after a high-volume breakout from consolidation, rallying to A$0.39. A proposed US$835M acquisition by Critical Metals Corp and renewed interest in its lithium and rare earth assets drove the surge.
1414 Degrees (ASX:14D) Breaks Out Again on Massive Volume. Will the prior pattern repeat?
1414 Degrees is an ASX-listed cleantech company developing silicon-based thermal storage, hydrogen and battery materials; investor interest reflects Aurora and SiNTL progress, fresh $2.69 million funding, and a high-volume share-price breakout that now needs follow-through.
ClearVue Technologies (ASX: CPV): Base-Building at Key Support, Is a Trend Reversal Finally Ahead?
ClearVue Technologies develops solar glass for energy-generating buildings. A recent Cyprus contract, improved losses, and reduced dilution sparked a bounce from key support, but the broader trend remains bearish, with confirmation of reversal dependent on stronger volume and sustained commercial traction.
Racura Oncology (ASX: RAC) - A High-Risk, High-Reward Oncology Play
Racura Oncology (ASX: RAC) is executing on a bold clinical strategy centered on RC220 (bisantrene reformulation), targeting both cardioprotection and enhanced anticancer activity in combination with doxorubicin. The company has dosed its first patient in a Phase 1 solid tumor trial, expanded into South Korea, and strengthened its clinical leadership team, all while maintaining disciplined cash management (A$13.67m at June 2025) to fund operations into 2026. Though early-stage, RAC presents a compelling mid- to long-term optionality scenario for investors with conviction in cardio-oncology and specialty chemotherapy.
...